NEW YORK, Oct. 27, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Tyson Foods, Inc. (“Tyson” or the “Company”) (NYSE:TSN) and certain of its officers, on behalf of shareholders who purchased Tyson securities from November 23, 2015 and October 7, 2016, inclusive (the "Class Period").
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The complaint alleges that throughout the Class Period, defendants issued false and misleading statements and/or failed to disclose that Tyson Foods had devised to manipulate chicken prices and as a result, defendants’ statements were materially false and misleading at all relevant times. On September 2, 2016, news sources reported the filing of an antitrust lawsuit against Tyson Foods claiming that it conspired to change the price of broiler-chickens. On October 7, 2016, Pivotal Research downgraded Tyson from “buy” to “sell,” noting apprehensions about a "powerfully convincing" class action against Tyson and some of its industry peers as defendants, alleging price collusion in the broiler-chicken market. The complaint alleges that at the beginning of 2008, Tyson and several other companies conspired by sharing proprietary data and reducing production to support prices. Following this news, Tyson stock has dropped as much as $8.53, or 11.47%, to $65.85 during intraday trading on October 7, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/tsn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Tyson you have until December 16, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



